In my December 7 article entitled Time To Buy Universal Display, I recommended readers sell Apple (AAPL) and buy Universal Display (PANL). Now, nearly 3 months later, I'm recommending the exact opposite. PANL is a world leader in the development of innovative OLED technology for use in flat panel displays, lighting and organic electronics, and is a great company, but now is the time to take profits in PANL and buy AAPL on the dip. Here's why:

1. My original article most dealt with the price and valuation by the numbers with AAPL being short-term overpriced and PANL being short-term underpriced. Since that time, PAN has run from $26.70 to $32.00, a gain +19.9%. At the same time, AAPL has fallen from $533.25 to $430.47, a loss of $102.78 per share or -19.3%. Through the successful execution of this strategy, one can now can nearly 50% more AAPL shares

Many real estate investment trusts (REITs) can be quite tempting as the housing market seems to be on the mend and experiencing a revival. What appears to be a bonus, a huge bonus, is that many of these REITs are flashing what looks like exceptionally high dividend yields. There's only one catch, and it's a biggie: many of these dividend yields are a mirage.

Don't get me wrong. REITs can potentially make great investments. Just be cautious when relying on dividend yield for many of them. Often the reason for the high dividend yield is because it's fake value. REITs, by their structure to save on taxes, have to pay out their net incomes in the form of dividends to shareholders. But then the same REITs turn around and raise capital at the expense of the very shareholders they are paying a dividend to, but

Smartphone and tablet cover maker ZAGG (ZAGG) reported 2012 earnings Tuesday night that knocked the ball out of the park across all metrics. ZAGG makes and sells affordable invisible protective shields for everything from iPods to smartphones to tablets. Unfortunately the only type of cover it doesn't sell, is one that allows shorts to "cover" their positions cheap. Shorts had been recklessly piling into ZAGG, clearly not expecting the report which much have hit them like a 2 X 4 in the head. At last count short interest was a staggering 8,848,900 which represents a short ratio of 12.8.

In the Q3 report, ZAGG had missed analyst estimates rather badly and shorts were clearly thinking ZAGG's best days were behind it. They were clearly wrong. The Q4 report and the outlook for 2013 blew away analyst expectations. Now with the cheap valuation ZAGG has in light of

"If you spend more than 13 minutes analyzing economic and market forecasts, you've wasted 10 minutes." --Peter Lynch

I found this well written and intriguing Seeking Alpha article entitled 20 Signs The U.S. Economy Is Heading For Big Trouble In The Months Ahead to contain content that I found to be quite compelling and even a bit frightening. It paints a very dark future for America's economy in 2013. The skeptic in me was inspired to research each bullet point more closely to see if perhaps the list was cherry picked or created while under a fog of confirmation bias, something I've been guilty of myself at times.

My article, in response, is an exercise in balance to illustrate how complicated it is to predict the future of the economy especially in the short term ("months") and even more difficult to predict when only using simple bullet points.

The Amarin (AMRN) long thesis, at face value, seems to make logical sense. It developed an EPA-only (ethyl eicosapentaenoic acid) fish oil pill that, unlike its competitors, is lacking in the bad stuff Docosahexaenoic acid (DHA) while providing a larger more effective dose of the EPA good stuff. Worse, in order to get an equal amount of the good stuff a patient would have to inject fistfuls of the OTC equivalent. The only other prescription competitor is GlaskoSmithKline's (GSK) Lovaza which is full of the bad stuff and therefore not nearly as effective as Vascepa. And while bulls will admit that the pricing of Vascepa will certainly be much higher than OTC pills, the patients won't care because insurance will cover the bulk of it, leaving them with a cheaper copay. So with that, AMRN is well positioned to go onto making billions in profitable drug sales. Right? The

It is finally official now. One-trick pony Amarin Corporation (AMRN) finally has its Vascepa "drug" available for prescription and sale and is 100% depending on its sales reps to push it (as opposed to a partner or sale of the company). I say "drug" in quotes because even though it's only available by prescription, Vascepa is simply an omega-3 fatty acid supplement. Omega-3 fatty acids are also marketed by other companies as non-prescription dietary supplements. As a result, Vascepa would be subject to non-prescription competition and consumer substitution. What supposedly distinguishes Vascepa from other fish oil pills is that it is "not less than 96%" ethyl eicosapentaenoic acid (EPA) while other fish oil pills contain a significant amount of docosahexaenoic acid (DHA) which is said to raise "bad" cholesterol as a side effect with traditional fish oil pills.

Less side effects is great, but in the end the

The market in general and medical-related stocks in particular continue to be on fire. It's times like this when people tend to sell their losers and put more money to work in new stocks. This is a time when oversold stocks can potentially make for very profitable trades, especially among ones that have extra large short interest. Profit taking works in both directions, and shorts will often take their profits and cover during this time. With increased optimism, volume, and volatility in the markets and medical stocks, these bounces can be quite pronounced.

I performed a screen search for oversold medical equipment and biotech stocks that fell between 6% and 10% last week. By limiting the fall to under 10%, this filters out many of the stocks that had bad fundamental news since usually if a medical stock sells off that severely, there's usually a fundamental reason for it such

Green Mountain Coffee (GMCR) got clipped in after hours following its earnings release Wednesday, February 6. The report included a slightly weaker-than-analyst-expectations outlook for fiscal Q2 sales of around 4% below consensus, but an EPS outlook inline with estimates. EPS beat by a wide margin of .11 per share coming in at .76 per share versus a .65 estimate. While there's always a risk of worse setbacks or new emerging competition, the sell-off seems way over done. Here's five reasons to be bullish on GMCR.

1. Guidance for 2013

Slightly lower sales outlook for Q2 should almost be irrelevant if not entirely irrelevant when considering that full year guidance was indeed inline with estimates. The overall fiscal year should play a larger role in investor valuation than a single quarter. Furthermore, did anybody bother to do the algebra? With full

NetSol (NTWK) describes itself as a worldwide provider of global IT and enterprise application solutions that include credit and finance portfolio management systems, SAP consulting and services, custom development, systems integration, and technical services for the global Financial, Leasing, Insurance, Energy, and Technology markets. Headquartered in Calabasas, Calif., NetSol's product and services offerings have achieved ISO 9001, ISO 20000, ISO 27001, and SEI (Software Engineering Institute) CMMI (Capability Maturity Model) Maturity Level 5 assessments, a distinction shared by only 178 companies worldwide. The company's clients include Fortune 500 manufacturers, global automakers, financial institutions, utilities, technology providers, and government agencies. NTWK's fiscal Q2 ending December 31, 2012 is expected to be reported. Here's 5 reasons to be bullish now ahead of its earnings report and beyond.

(1) CEO confidence

In a Christmas eve letter to shareholders just before the quarter ended, CEO Najeeb Ghauri was bragging up a storm about

Celsion (CLSN) announced today that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC). The HEAT Study was designed to show a 33% improvement in PFS with 80% power. We will get more details from CLSN management as they analyze the data further. Meantime, I can only speculate on three realistic possibilities on why I was wrong, which I will detail below.

It seemed like such a sure thing. We had the enrollment data. We had the progression-free survival (PFS) data. We had what the placebo arm should do. We had the data to calculate how long the average patient was in the trial. We had the data to calculate how many patients should have had a PFS event. And most importantly, based on all this data, we had what seemed to

Gray Television (GTN) is a television broadcast company which owns and operates television stations broadcasting 40 primary channels and 45 secondary channels in 30 television markets. 19 channels are CBS affiliates, 10 are NBC affiliates, and 9 are ABC affiliates. GTN's fourth quarter earnings ending December 31 will be released in about a month. Here's 5 reasons to be bullish on GTN now ahead its earnings report and beyond.

1. GTN guided for a very big quarter primarily due to ad spending across its networks that "earned significantly more political advertising revenue than previously anticipated." GTN is estimating record political ad spending in Q4 of between $85 and $86 million, beating the previous company record of $57.6 million in 2010 by over 47%. This will bring full year 2012 total revenues to over $400 million compared to the previous record of $346.1 million in 2010. Average analyst estimated EPS

Celsion (CLSN) is very close to its top-line release of its Phase III study, called the HEAT trial, designed to show that ThermoDox + RFA treatment improves the time to progression of HCC liver cancer by at least 33% for patients with large tumors versus RFA alone. In my previous Part 1 to this article I presented what I believe is a mathematical proof that Celsion's ThermoDox has worked based on valuable data already in front of you over the course of the trial to 380 PFS events. Now I will show more interesting, more pronounced data midway through the trial along with further analysis. My data and analysis will show a reasonable mathematical expectation of:

ThermoDox has delayed the progression of the disease over the control arm by at least 111%.

THE PROOF:

The two most likely causes cited by the FDA that constitute a progression-free

"...one of the most important new drugs in a generation"
"...perhaps a blockbuster by anybody's definition"
-- Celsion (CLSN) CEO Michael H. Tardugno in a recent presentation.

There's been a lot of scientific and medical debate from bulls and bears as to why the Celsion ThermoDox drug in Phase III results should work or not. Forget "should" -- there's already enough data publicly revealed to prove mathematically that ThermoDox already has worked. I'll explain.

There have been many great articles already recently that dive into the scientific and medical background about this study. I will direct you to my personal two favorite articles (here and here) which I agree with its contents and leave it at that. This article's intent is to move on from theory and analyze what is already a historically revealed fact.

Celsion is literally any day away from its top-line

There has been a lot of negative hype concerning the iPhone 5 this holiday season. Rumors have ranged from weak demand to supplier component shortages to orders being cut. Taken together, these rumors have played a role in collapsing the stock price of Apple (AAPL) from over $700 in September to barely over $500 currently, as people fear AAPL estimates will come up short vs. last year. All of this fear is based on nonsense. Here's why:

1. "Orders Cut, Oh No!" -- We've Seen This Movie Before

Why are people, including analysts, worried about rumors of orders being cut? AAPL's 10-K specifically states:

In the company's experience, the actual amount of product backlog at any particular time is not a meaningful indication of its future business prospects. In particular, backlog often increases in anticipation of or immediately following new product introductions as customers anticipate shortages. Backlog is

Celsion (CLSN) shareholders are in the final days ahead of the expected January 2013 top-line release of "the Phase III HEAT Study, a multinational, double-blind, placebo-controlled, pivotal study of ThermoDox in combination with radiofrequency ablation ((RFA)) for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer" in a fantastic Cinderella-like story. This is an all-or-nothing, winner-takes-all (bulls or bears) binary event. This one piece of news will likely determine if CLSN gets to go to the big oncology ball dressed in a beautiful treatment for HCC so effective it may even be a cure for many people with advanced liver cancer - or results that leave CLSN home in rags.

There's been a very highly emotional debate lately for both bulls and bears with both sides at risk of losing a substantial amount of money. With the stock trading near the

This coming week is traditionally the annual Santa Claus rally. This is a time when stocks breaking out can potentially make for very profitable trades, especially among ones that have extra large short interest and may be undergoing a short squeeze. With the fears of the fiscal cliff still looming, biotechs can provide some perceived safety as they are largely less affected by the economy than companies in many other industries.

I performed a screen search for biotech stocks that rallied at least 20% last week. I then further filtered down my search to only stocks over $1.00 as they usually can't be legally shorted much anyway and my attempt is to locate those undergoing or possibly about to undergo a short squeeze. There are five stocks that resulted from my screen, and they all happened to have decent sized short ratios. Use this list only as a

This coming week is traditionally the annual Santa Claus rally. This is a time when oversold stocks can potentially make for very profitable trades, especially among ones that have extra large short interest. Profit taking works in both directions, and shorts will often take their profits and cover during this time. With the fears of the fiscal cliff still looming, medical stocks can provide some perceived safety as they are largely less affected by the economy than companies in many other industries.

I performed a screen search for oversold medical equipment and biotech stocks that fell between 6% and 10% last week. By limiting it to under 10%, this filters out many of the stocks that had bad fundamental news since usually if a medical stock sells off that severely, there's usually a fundamental reason for it. I then further filtered down my search to only stocks with a short

I've been tracking the implosion of the core business of Zynga (ZNGA) since my frist article September 27 and more details November 30th, illustrating how quickly popularity declines week after week with Zynga's most popular games. In response to its declining business, ZNGA is making a great push into mobile gaming as the company struggles to turn things around. Most of Zynga's games could not be played on the BlackBerry operating systems of the past which has restricted the overall user base to Zynga's games, but perhaps the new BlackBerry 10 will change that and help save ZNGA. I'll explain.

First, a bit of background on my Zynga tracking. As explained in Zynga's most recent 10Q filing, their top 3 to 5 games can be anywhere from 50% to 80% of the entire company's revenues so I find it important to track the monthly average

Amarin (AMRN) has been getting beaten up lately with missed expectations, angry and disappointed shareholders, and bad news raining down like cats and dogs. I detailed a the issues bit in my first AMRN article titled "Amarin Corporation Drops A Double Dose Of Bad News," and then again in my article titled "Forget Amarin: Buy Celsion For A Bigger Score." So the bad news is out, and AMRN is due for a bounce right? I don't think so. I believe AMRN will continue to slide down. Here are four reasons why:

1. No Equity Financing

The terms of new no equity financing sound as if AMRN sold its soul to the Cayman Islands devil. Under the terms of the agreement with "Biopharma Secured Debt Fund II Holdings Cayman LP," AMRN will be likely be paying a nosebleed 12%-14% interest on $100 million, adding more than

I'm always on the look out for stocks either in the midst of a short squeeze or poised to potentially have one, as detailed in one of my recent articles. Searching for these stocks as a starting point then reading up on why they're rallying can lead to very profitable trade ideas.

I did a screen for stocks that hit new 52 week highs on Thursday. I then further refined the list to stocks that have large short positions. 5 stocks from the result of my search are below, sorted by short ratio from highest to lowest. Use this list only as a mere first step for possible ideas warranting further research:

(1) The Boston Beer Company, Inc. (SAM) engages in the production and sale of alcohol beverages primarily in the United States, Canada, Europe, Israel, the Caribbean, the Pacific Rim, and Mexico. It hit a new 52